{"id":53660,"date":"2023-09-20T09:49:03","date_gmt":"2023-09-20T09:49:03","guid":{"rendered":"https:\/\/medsname.com\/floslo\/"},"modified":"2026-04-30T10:25:10","modified_gmt":"2026-04-30T10:25:10","slug":"floslo","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/floslo\/","title":{"rendered":"Floslo"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Floslo<\/strong> obsahuje solifenacin succinate 5 mg \/ 10 mg<\/strong> v\u00fdrobce Intas Pharma. Pou\u017e\u00edv\u00e1 se p\u0159i p\u0159\u00edznac\u00edch hyperaktivn\u00edho mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e (OAB) \u2014 urgentn\u00ed nucen\u00ed na mo\u010den\u00ed, \u010dast\u00e9 mo\u010den\u00ed a urgentn\u00ed inkontinence. U\u017e\u00edvejte p\u0159esn\u011b podle pokyn\u016f l\u00e9ka\u0159e \u2014 ned\u00e1vkujte si l\u00e9k sami.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

\ud83d\udd12 \u0160ifrovan\u00e9 platby<\/strong> \u00b7 \ud83d\udcb3 Ov\u011b\u0159en\u00fd platebn\u00ed procesor<\/strong> \u00b7 \ud83d\ude9a Doprava do cel\u00e9ho sv\u011bta<\/strong> \u00b7 \u2b50 4,9\/5 od 1 400+ z\u00e1kazn\u00edk\u016f<\/strong><\/div>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Ka\u017ed\u00e1 \u0161ar\u017ee je dod\u00e1v\u00e1na od v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Objedn\u00e1vky jsou odes\u00edl\u00e1ny v neutr\u00e1ln\u00edch obalech od na\u0161ich partnersk\u00fdch distribu\u010dn\u00edch center a jsou chr\u00e1n\u011bny na\u0161\u00edm Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>. Slou\u017eili jsme ji\u017e 1 400+ ov\u011b\u0159en\u00fdm z\u00e1kazn\u00edk\u016fm<\/strong> s pr\u016fm\u011brn\u00fdm hodnocen\u00edm 4,9\/5<\/strong> nap\u0159\u00ed\u010d v\u00edce ne\u017e 600 l\u00e9ky.<\/p>\n

Co je Floslo a jak p\u016fsob\u00ed<\/h2>\n

Floslo obsahuje solifenacin succinate<\/strong>, selektivn\u00ed kompetitivn\u00ed antagonista muskarinov\u00fdch receptor\u016f M3<\/strong>. Blokov\u00e1n\u00edm M3 receptor\u016f na detruzoru (hladk\u00fd sval mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e) solifenacin sni\u017euje mimovoln\u00ed kontrakce b\u011bhem f\u00e1ze pln\u011bn\u00ed m\u011bch\u00fd\u0159e a tlum\u00ed epizody urgentn\u00edho nucen\u00ed, \u010dast\u00e9ho mo\u010den\u00ed a urgentn\u00ed inkontinence.<\/p>\n

Solifenacin je indikov\u00e1n k symptomatick\u00e9 l\u00e9\u010db\u011b hyperaktivn\u00edho mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e (OAB)<\/strong> s urgentn\u00edm nucen\u00edm na mo\u010den\u00ed, \u010dast\u00fdm mo\u010den\u00edm a urgentn\u00ed inkontinenc\u00ed. Je to jeden z celosv\u011btov\u011b nej\u010dast\u011bji p\u0159edepisovan\u00fdch antimuskarinik\u016f pro OAB d\u00edky jednodenn\u00edmu d\u00e1vkov\u00e1n\u00ed a relativn\u011b p\u0159\u00edzniv\u00e9mu toleran\u010dn\u00edmu profilu.<\/p>\n

D\u00e1vkov\u00e1n\u00ed a zp\u016fsob u\u017e\u00edv\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Skupina pacient\u016f<\/th>\nDoporu\u010den\u00e1 d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Dosp\u011bl\u00ed s OAB \u2014 po\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/td>\n5 mg jednou denn\u011b<\/strong><\/td>\n<\/tr>\n
Po 4 t\u00fddnech v p\u0159\u00edpad\u011b pot\u0159eby d\u00e1vku zv\u00fd\u0161it<\/td>\nZv\u00fd\u0161it na 10 mg jednou denn\u011b<\/strong><\/td>\n<\/tr>\n
T\u011b\u017ek\u00e9 ren\u00e1ln\u00ed posti\u017een\u00ed (eGFR <30)<\/td>\nMaxim\u00e1ln\u00ed d\u00e1vka 5 mg\/den<\/td>\n<\/tr>\n
St\u0159edn\u011b t\u011b\u017ek\u00e9 po\u0161kozen\u00ed jater (Child-Pugh B)<\/td>\nMaxim\u00e1ln\u00ed d\u00e1vka 5 mg\/den<\/td>\n<\/tr>\n
T\u011b\u017ek\u00e9 jatern\u00ed po\u0161kozen\u00ed (Child-Pugh C)<\/td>\nVyhnout se<\/td>\n<\/tr>\n
Sou\u010dasn\u00e9 u\u017e\u00edv\u00e1n\u00ed siln\u00e9ho inhibitoru CYP3A4<\/td>\nMaxim\u00e1ln\u00ed d\u00e1vka 5 mg\/den<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Polykat cel\u00e9, s j\u00eddlem nebo nala\u010dno, ve stejnou denn\u00ed dobu.<\/strong> \u010c\u00e1ste\u010dn\u00e9 zlep\u0161en\u00ed se objev\u00ed b\u011bhem 1\u20132 t\u00fddn\u016f; pln\u00fd \u00fa\u010dinek nast\u00e1v\u00e1 za 4\u20136 t\u00fddn\u016f. Zv\u00fd\u0161en\u00ed na 10 mg pouze v p\u0159\u00edpad\u011b nedostate\u010dn\u00e9 odpov\u011bdi na 5 mg po 4 t\u00fddnech \u2014 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (zejm\u00e9na sucho v \u00fastech a z\u00e1cpa) se p\u0159i vy\u0161\u0161\u00ed d\u00e1vce v\u00fdznamn\u011b zvy\u0161uj\u00ed.<\/p>\n

\n

\u26a0 Anticholinergn\u00ed z\u00e1t\u011b\u017e \u2014 zkontrolujte sou\u010dasn\u011b u\u017e\u00edvan\u00e9 l\u00e9ky<\/strong><\/p>\n

Solifenacin p\u0159isp\u00edv\u00e1 k celkov\u00e9 anticholinergn\u00ed z\u00e1t\u011b\u017ei. U star\u0161\u00edch dosp\u011bl\u00fdch je trvale vysok\u00e1 anticholinergn\u00ed z\u00e1t\u011b\u017e spojena s poklesem kognitivn\u00edch funkc\u00ed a zv\u00fd\u0161en\u00fdm rizikem demence<\/strong>. Prov\u011b\u0159te dal\u0161\u00ed anticholinergn\u00ed l\u00e9ky (tricyklick\u00e1 antidepresiva, sedativn\u00ed antihistaminika, oxybutynin, hyoscin, n\u011bkter\u00e9 l\u00e9ky na Parkinsonovu chorobu). Mirabegron (beta-3 agonista bez anticholinergn\u00edho \u00fa\u010dinku) je \u010dist\u0161\u00ed alternativou, pokud je z\u00e1t\u011b\u017e probl\u00e9mem.<\/p>\n<\/div>\n

Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Vedlej\u0161\u00ed \u00fa\u010dinek<\/th>\nFrekvence u d\u00e1vky 5 mg<\/th>\nFrekvence u d\u00e1vky 10 mg<\/th>\n<\/tr>\n<\/thead>\n
Sucho v \u00fastech<\/td>\n~11%<\/td>\n~28%<\/td>\n<\/tr>\n
Z\u00e1cpa<\/td>\n~5%<\/td>\n~13%<\/td>\n<\/tr>\n
Rozmazan\u00e9 vid\u011bn\u00ed<\/td>\n~4%<\/td>\n~5%<\/td>\n<\/tr>\n
Nesn\u00e1\u0161enlivost \u017ealudku \/ nevolnost<\/td>\n~3%<\/td>\n~4%<\/td>\n<\/tr>\n
Such\u00e9 o\u010di<\/td>\nB\u011b\u017en\u00e9<\/td>\nB\u011b\u017en\u00e9<\/td>\n<\/tr>\n
Zadr\u017eov\u00e1n\u00ed mo\u010di<\/td>\nM\u00e9n\u011b \u010dast\u00e9<\/td>\nM\u00e9n\u011b \u010dast\u00e9<\/td>\n<\/tr>\n
Prodlou\u017een\u00ed QT intervalu<\/td>\nVz\u00e1cn\u00e9<\/td>\nVyvarujte se u\u017e\u00edv\u00e1n\u00ed p\u0159i syndromu dlouh\u00e9ho QT<\/td>\n<\/tr>\n
Kognitivn\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/td>\nM\u00e9n\u011b \u010dast\u00e9<\/td>\nV\u00fdrazn\u011bj\u0161\u00ed u star\u0161\u00edch dosp\u011bl\u00fdch<\/td>\n<\/tr>\n
Akutn\u00ed glaukom s uzav\u0159en\u00fdm \u00fahlem<\/td>\nVz\u00e1cn\u00e9<\/td>\nOftalmologie v tent\u00fd\u017e den<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Interakce l\u00e9k\u016f<\/h2>\n\n\n\n\n\n\n\n\n\n
Kombinace<\/th>\n\u00da\u010dinek<\/th>\n\u00da\u010dinek<\/th>\n<\/tr>\n<\/thead>\n
Siln\u00e9 inhibitory CYP3A4 (ketokonazol, itrakonazol, klarithromycin, ritonavir)<\/td>\nHladiny solifenacinu stoupaj\u00ed<\/td>\nMaxim\u00e1ln\u00ed d\u00e1vka 5 mg\/den<\/td>\n<\/tr>\n
Siln\u00e9 induktory CYP3A4 (rifampicin, fenytoin, karbamazepin)<\/td>\nZtr\u00e1ta \u00fa\u010dinku<\/td>\nP\u0159echod na alternativu bez vlivu na CYP3A4<\/td>\n<\/tr>\n
Jin\u00e1 anticholinergika<\/td>\nAditivn\u00ed z\u00e1t\u011b\u017e<\/td>\nVyhn\u011bte se kombinaci<\/td>\n<\/tr>\n
L\u00e9ky prodlu\u017euj\u00edc\u00ed QT interval (sotalol, amiodaron, citalopram > 20 mg, metadon)<\/td>\nAditivn\u00ed \u00fa\u010dinek na QT interval<\/td>\nVyvarujte se kombinace<\/td>\n<\/tr>\n
Bisfosfon\u00e1ty<\/td>\nSolifenacin m\u016f\u017ee zhor\u0161it podr\u00e1\u017ed\u011bn\u00ed j\u00edcnu<\/td>\nU\u017e\u00edvejte odd\u011blen\u011b, se\u010fte vzp\u0159\u00edmen\u011b 30 minut po bisfosfon\u00e1tu<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Kdo by nem\u011bl u\u017e\u00edvat Floslo<\/h2>\n